Illustrative projections
01 / 15
LONGEVA

I spent my career changing how people look. This changes how they age.

A physician-founded Abu Dhabi longevity platform: a proprietary clinical engine, a membership model, built to scale across the emirates.

Dr. Miguel Bravo  |  Board-certified physician, DOH-licensed, Abu Dhabi
Illustrative projections
The category02

Abu Dhabi did not wait for longevity medicine. It legislated it.

We build inside a state research agenda, moving with the government rather than ahead of it.

  • DOH HLMC license, April 2025: the world's first Healthy Longevity Medicine Centre framework, a dedicated licensable facility type.
  • The April 2025 Declaration on longevity, precision medicine and research, signed by DOH, M42, PureHealth, Illumina, NYU Abu Dhabi and the University of Pennsylvania.
  • Hub71+ Life Sciences with DOH and the Emirates Drug Establishment as founding partners; the Emirati Genome Programme (700,000+ whole genomes).
The buyer is here and self-paying
~240k
UAE high-net-worth individuals, ~USD 785bn held
#1
Globally for millionaire inflows (~9,800 net, 2025)
12 to 120k
AED willingness-to-pay band for physician-led programs
Live DOH facility-registry check run before each pitch to confirm the current count of licensed HLMCs.
The unfair advantage03

The hardest part is already built, licensed, and running.

Dr. Miguel Bravo is a board-certified plastic surgeon and a practicing longevity physician, DOH-licensed and operating in Abu Dhabi. The outside-and-inside story is his story: a career changing how people look, now changing how they age.

  • A live clinical engine: labs in native units, Metabolic Optimization Scorecard, multi-specialist synthesis as one signed voice.
  • A real product the diligence room can see: sample Scorecards, the branded report, audit-trail design, patient count to date.
  • Owned premium brand and CRM stack. We are productizing something that already works, not starting from zero.

Bandwidth: the founder's primary role is platform and CMO; surgery is partnered, capacity-capped, and sits in a separate practice.

The opening04

The premium, physician-led slot is open. The play is to take it first and lock it.

Network Single site Wellness / biohacking Clinical credibility Dubai biohacking / IV Hospital-anchored HLMCs Longeva Window, then locked by retention
  • Credible, founder-led, network-model longevity is the white space: Dubai is crowded with IV and biohacking; Abu Dhabi's licensed HLMCs are hospital-adjacent.
  • Stated honestly as a 12 to 18 month timing window, not permanent structural white space.
  • M42 or PureHealth could move. The answer is first-mover plus membership lock-in, not a claim that the gap stays open.
The flagship05

The flagship is the credibility anchor. Its signature is surgical-metabolic.

The signature, outside-and-inside made clinical
  • Ultrasound-guided, tissue-respecting surgery paired with evidence-based perioperative optimization.
  • Quantified recovery: wearables as perioperative medical tools and approved metabolic management.
  • Approved agents only. No named peptides; research is the legitimate evidence path, never a marketed intervention.

Capital efficiency: Dr. Bravo's own practice co-locates in the flagship. The flagship doubles as his clinic; surgery runs on partnered-hospital privileges; his practice is a separate entity, and the platform captures referral, rent and services.

Owned versus partnered diagnostics

Own

DEXA, VO2max / CPET, ECG, organ ultrasound, vascular stiffness, bioimpedance, phlebotomy, premium fit-out, the clinical software.

Partner / rent

Full-body and brain MRI, CCTA with AI plaque analysis, the wet lab and specialty send-outs (biological-age clocks, advanced markers, MCED).

~8,000 to 12,000 sq ft. We own what is cheap, repeated, and data-generating; we rent the heavy iron. Imaging-partner LOI flagged before opening.

The software06

The clinical workflow that lets one physician do a multi-specialist's work, on the record.

Labs, any units Intake / history Serial trajectory Clinical engine Multi-specialist synthesis as one voice Evidence-tiered logic Red-flag safety net Signed branded report + Scorecard Audit trails  |  physician sign-off on every output  |  SaMD-aware, never autonomous
  • Today it is a margin lever and a compliance-grade workflow: it compresses physician time per member while keeping the physician accountable on the record.
  • Shown working beyond the founder: scalable, multi-user, exportable. Software-enabled is substance, not decoration.
  • The deeper platform and B2B layer is labeled Next-round upside not the valuation basis.
Sequencing07

Online now, then the network.

Phase 0 physician-led, digitally-delivered membership is live now: asset-light, on the existing license and engine, de-risking demand before any building.

Online reach + annuity + follow-up Synchronous-anchored, async-supported Flagship high-touch In-person upsell: injectables, IV, advanced imaging Satellites
Verified telehealth basis
  • Operate under the existing DOH license: teleconsult, home labs, ordinary e-prescribing, follow-up.
  • Controlled meds, peptides and injectables are in-person only, which is the clean flagship upsell hook.
  • Not async-first: a live teleconsult anchors the relationship; async carries the rest of the year.
Unit economics08

A membership business with a high-ticket front door.

Revenue layerIndicative AED
1. Comprehensive evaluation (one-time front door)12,000 to 25,000
2. Annual program (the retention engine)30,000 to 120,000 / yr
3. Advanced-diagnostic add-ons2,000 to 18,000 each
4. Evidenced HRT / GLP-1 optimization + re-tests1,500 to 6,000 / cycle
5. Concierge tier (apex)150,000 to 350,000+ / yr

Peptides are not shown as a revenue line, pending DOH guidance in writing. Approved agents only.

45 to 70k
Blended AED revenue per active member per year
55 to 65%
Contribution margin, conservative full-physician-review case (the measured physician-cost-per-member line)

Aesthetics referral economics: longevity members refer into Dr. Bravo's co-located practice, lifting LTV via cash-pay cross-sell to the same HNWI base, captured as platform referral economics. Zero aesthetics capex; surgery on partnered-hospital privileges.

The spine of the raise09

Fund us to prove one number: members renew, at a CAC that works.

THE COHORT MODEL CAC by channel Evaluation to membership conversion Annual net renewal Physician fully-loaded cost LTV : CAC clears stated threshold
  • Everything downstream (satellites, flywheel, B2B) is contingent on this number.
  • The paid founding-flagship-deposit step-up test: a refundable deposit is purchase intent, not a free waitlist name.
  • The kill-gate: if online clears but deposits miss the threshold, we re-scope before flagship capex. Phase 0 is built to surface that, not bury it.
Market10

A defensible revenue ceiling, built from the buyer up.

AD + Dubai HNWI households x Realistic capture % x Blended ARPU = Defensible serviceable obtainable market
  • The ceiling is built from the buyer up, not from a top-down ring chart.
  • Willingness-to-pay band held to the product-relevant AED 12k to 120k.
Context footnotes only: the ~USD 4 to 6bn UAE longevity slice and the ~USD 32bn wellness-bundled figure are not the basis of the model.
Traction11

Not a hypothesis. A working system, a licensed founder, a retention-gated proof plan.

Demand-proof register
  • Phase 1a numbers: paying members, 12-month retention, CAC by channel, contribution with measured physician-COGS.
  • Paid founding-flagship deposits as the falsifiable step-up signal.
Delivery-risk package
  • Costed flagship pro forma.
  • Partner-hospital LOI for surgical routing.
  • Named clinical lead; research-facility authorization.
In hand Flagship open + licensed Retention / CAC gate Satellite #1 reproduces
Upside12

Once proven in our own centers, the workflow licenses white-label.

Owned network, proven in-house first Flagship + satellites + the clinical engine White-label software layer Clinics and health systems, regionally OPTIONALITY
  • High-margin, capital-light, riding infrastructure we already built for ourselves.
  • Explicitly Next-round upside not the base case. Prove it in-house first, then license from a position of evidence.
The moat13

The data and evidence engine, built honestly.

A longitudinal, units-normalized dataset feeds real-world evidence and publications: DOH-aligned, evidence-based longevity, not biohacking.

Now

Physician brand + DOH license

Earned, in hand, not replicable by software.

Now

Compliance-grade workflow

Audit trails, sign-off, SaMD-aware posture.

Building

Membership switching cost

Serial trajectory data makes leaving costly.

Phase 3+

Data + evidence flywheel

Complementary to the state's genomics, not competing.

The research arm
  • DOH-authorized facility plus a research ethics committee.
  • RWE on our own cohort first, then partner-led studies with M42 and NYUAD.
  • R&D-tax-credit and partnership optionality.

Incumbents have balance sheets and population genomics. We have brand plus workflow plus a head start, locked by retention.

Discipline14

We own the cheap, repeatable assets. We rent the heavy iron.

Own

DEXA, VO2max, ultrasound, phlebotomy, fit-out, the software. Cheap, repeated, data-generating.

Rent

MRI, CCTA, wet lab, and the OR. Heavy, lumpy, utilization-sensitive iron.

Owned OR is explicitly not in use-of-proceeds. Flagship modeled as a base case plus contingency; imaging-partner LOI; a SaMD regulatory read; margins on the conservative-review case.

Top risks, each with a mitigation
Retention / CACThe seed is gated on proving exactly this.
Capex intensityBase case + contingency; owned-MRI downside still clears.
Regulatory / SaMDDecision-support only; margin assumes full review.
CompetitionFirst-mover plus membership lock-in.
Key-personSoftware standardizes quality; named site physicians.
The ask15

Seed the flagship. Prove retention. Then raise the rollout from evidence.

Phase 0Online now Phase 1Flagship Retention gate Phase 2Satellites Phase 3GCC / platform / B2B

Seed

~AED 11 to 22M  (~USD 3 to 6M)

Build the flagship plus productize the software. Gated on Phase 1a retention / CAC and paid deposits.

Growth

~AED 55 to 110M  (~USD 15 to 30M)

Satellites, from proven economics, after the gate.

All AED and USD figures are illustrative projections, to be confirmed against live Abu Dhabi lease, fit-out, lab and DOH licensing costs.